- Home
- CVKD vs TPST Comparison
CVKD vs TPST Comparison
Compare CVKD & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- TPST
- Stock Information
- Founded
- CVKD 2022
- TPST 2011
- Country
- CVKD United States
- TPST United States
- Employees
- CVKD N/A
- TPST N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- TPST Health Care
- Exchange
- CVKD Nasdaq
- TPST Nasdaq
- Market Cap
- CVKD 29.5M
- TPST 33.0M
- IPO Year
- CVKD 2023
- TPST N/A
- Fundamental
- Price
- CVKD $12.92
- TPST $7.40
- Analyst Decision
- CVKD Strong Buy
- TPST Hold
- Analyst Count
- CVKD 1
- TPST 3
- Target Price
- CVKD $32.00
- TPST $30.00
- AVG Volume (30 Days)
- CVKD 31.8K
- TPST 241.4K
- Earning Date
- CVKD 08-06-2025
- TPST 08-07-2025
- Dividend Yield
- CVKD N/A
- TPST N/A
- EPS Growth
- CVKD N/A
- TPST N/A
- EPS
- CVKD N/A
- TPST N/A
- Revenue
- CVKD N/A
- TPST N/A
- Revenue This Year
- CVKD N/A
- TPST N/A
- Revenue Next Year
- CVKD N/A
- TPST N/A
- P/E Ratio
- CVKD N/A
- TPST N/A
- Revenue Growth
- CVKD N/A
- TPST N/A
- 52 Week Low
- CVKD $5.70
- TPST $5.35
- 52 Week High
- CVKD $22.90
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- CVKD 53.25
- TPST 53.40
- Support Level
- CVKD $11.00
- TPST $7.06
- Resistance Level
- CVKD $13.24
- TPST $7.18
- Average True Range (ATR)
- CVKD 1.10
- TPST 0.26
- MACD
- CVKD 0.25
- TPST 0.02
- Stochastic Oscillator
- CVKD 94.47
- TPST 90.05
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.